Answers are grounded in this paper and cite their sources.
SUMMARY Use of the cell saver in oncologic surgery is controversial because of the risk of reinfusion of cancer cells remaining in the packed erythrocytes. Experimental and clinical studies have indeed confirmed the presence of residual cancer cells in packed red cells. However, six clinical studies with a limited number of patients showed no metastatic spread after processing of the blood with a cell saver. The adjunctive use of a leukocyte depletion filter (LDF) greatly reduces the number of cancerous cells in the pack whereas irradiation of the pack with 50 Gy destroys all the cancer cells. Strictly speaking, the stringent application of this safety principle would require use of a cell saver only in conjunction with an irradiator. Studies indicate that cancer cell seeding from infiltrative tumors seems to be greater than that observed when a cell saver is used. In the final analysis, we feel that it is reasonable to use the cell saver in oncologic surgery, if possible with a leukocyte filter, not only in cases of unexpected bleeding risk but also during scheduled procedures with a high risk of massive blood loss.
No takes yet. Share an insight, caveat, or question.
Elias et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: